Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of rifampicin- or multidrug-resistant tuberculosis in Indonesia

被引:1
|
作者
Yunivita, Vycke [1 ,2 ]
Gafar, Fajri [1 ,3 ,4 ]
Santoso, Prayudi [5 ,6 ]
Chaidir, Lidya [2 ,7 ]
Soeroto, Arto Y. [5 ,6 ]
Meirina, Triana N. [8 ]
Te Brake, Lindsey [9 ]
Menzies, Dick [3 ,4 ]
Aarnoutse, Rob E. [9 ]
Ruslami, Rovina [1 ,2 ,4 ]
机构
[1] Univ Padjadjaran, Fac Med, Dept Biomed Sci, Div Pharmacol & Therapy, Bandung, Indonesia
[2] Univ Padjadjaran, Res Ctr Care & Control Infect Dis, TB Working Grp, Bandung, Indonesia
[3] Res Inst McGill Univ Hlth Ctr, Ctr Outcomes Res & Evaluat, Resp Epidemiol & Clin Res Unit, 5252 Blvd Maisonneuve Ouest,Off 3D 21, Montreal, PQ H4A 3S5, Canada
[4] McGill Univ, McGill Int TB Ctr, Montreal, PQ, Canada
[5] Univ Padjadjaran, Fac Med, Dept Internal Med, Div Respirol & Crit Care, Bandung, Indonesia
[6] Hasan Sadikin Gen Hosp, Bandung, Indonesia
[7] Univ Padjadjaran, Fac Med, Dept Biomed Sci, Div Microbiol, Bandung, Indonesia
[8] Univ Padjadjaran, Fac Med, Pharmacokinet Lab, Bandung, Indonesia
[9] Radboud Univ Nijmegen Med Ctr, Radboud Inst Med Innovat, Dept Pharm, Nijmegen, Netherlands
关键词
BACTERICIDAL ACTIVITY; CULTURE CONVERSION; TB PATIENTS; DRUGS; PHENOTYPE; GENOTYPE;
D O I
10.1093/jac/dkae057
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background :Pharmacokinetic data on high-dose isoniazid for the treatment of rifampicin-/multidrug-resistant tuberculosis (RR/MDR-TB) are limited. We aimed to describe the pharmacokinetics of high-dose isoniazid, estimate exposure target attainment, identify predictors of exposures, and explore exposure-response relationships in RR/MDR-TB patients. Methods: We performed an observational pharmacokinetic study, with exploratory pharmacokinetic/pharmacodynamic analyses, in Indonesian adults aged 18-65 years treated for pulmonary RR/MDR-TB with standardized regimens containing high-dose isoniazid (10-15 mg/kg/day) for 9-11 months. Intensive pharmacokinetic sampling was performed after >= 2 weeks of treatment. Total plasma drug exposure (AUC(0-24)) and peak concentration (Cmax) were assessed using non-compartmental analyses. AUC(0-24)/MIC ratio of 85 and C-max/MIC ratio of 17.5 were used as exposure targets. Multivariable linear and logistic regression analyses were used to identify predictors of drug exposures and responses, respectively. Results :We consecutively enrolled 40 patients (median age 37.5 years). The geometric mean isoniazid AUC(0-24 )and Cmax were 35.4 h center dot mg/L and 8.5 mg/L, respectively. Lower AUC0-24 and Cmax values were associated (P < 0.05) with non-slow acetylator phenotype, and lower Cmax values were associated with male sex. Of the 26 patients with MIC data, less than 25% achieved the proposed targets for isoniazid AUC(0-24)/MIC (n = 6/26) and C-max/MIC (n = 5/26). Lower isoniazid AUC0-24 values were associated with delayed sputum culture conversion (>2 months of treatment) [adjusted OR 0.18 (95% CI 0.04-0.89)]. Conclusions :Isoniazid exposures below targets were observed in most patients, and certain risk groups for low isoniazid exposures may require dose adjustment. The effect of low isoniazid exposures on delayed culture conversion deserves attention.
引用
收藏
页码:977 / 986
页数:10
相关论文
共 50 条
  • [1] Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis
    Gausi, Kamunkhwala
    Chirehwa, Maxwell
    Ignatius, Elisa H.
    Court, Richard
    Sun, Xin
    Moran, Laura
    Hafner, Richard
    Wiesner, Lubbe
    Rosenkranz, Susan L.
    de Jager, Veronique
    de Vries, Nihal
    Harding, Joseph
    Gumbo, Tawanda
    Swindells, Susan
    Diacon, Andreas
    Dooley, Kelly E.
    McIlleron, Helen
    Denti, Paolo
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2022, 77 (09) : 2489 - 2499
  • [2] Rationale for high-dose isoniazid in the treatment of multidrug-resistant tuberculosis
    Rieder, Hans L.
    Van Deun, Armand
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2017, 21 (01) : 123 - 124
  • [3] Rationale for high-dose isoniazid in the treatment of multidrug-resistant tuberculosis Reply
    Bollela, Valdes R.
    Caminero, Jose A.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2017, 21 (01) : 124 - 124
  • [4] Improved Outcomes With High-dose Isoniazid in Multidrug-resistant Tuberculosis Treatment in Haiti
    Walsh, Kathleen F.
    Vilbrun, Stalz Charles
    Souroutzidis, Ariadne
    Delva, Sobieskye
    Joissaint, Guy
    Mathurin, Laurent
    Ocheretina, Oksana
    Cremieux, Pierre
    Pape, Jean William
    Koenig, Serena P.
    CLINICAL INFECTIOUS DISEASES, 2019, 69 (04) : 717 - 719
  • [5] Pharmacokinetics of high-dose isoniazid in children affected by multidrug-resistant TB
    Winckler, J. L.
    Schaaf, H. S.
    Draper, H. R.
    McIlleron, H.
    Norman, J.
    van der Laan, L. E.
    Wiesner, L.
    Donald, P. R.
    Hesseling, A. C.
    Garcia-Prats, A. J.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2021, 25 (11) : 896 - +
  • [6] A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis
    Katiyar, S. K.
    Bihari, S.
    Prakash, S.
    Mamtani, M.
    Kulkarni, H.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2008, 12 (02) : 139 - 145
  • [7] A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis - Reply
    Katiyar, S. K.
    Bihari, S.
    Prakash, S.
    Mamtani, M.
    Kulkarni, H.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2008, 12 (09) : 1102 - 1102
  • [8] High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova
    Chesov, Dumitru
    Ciobanu, Nelly
    Lange, Christoph
    Heyckendorf, Jan
    Crudu, Valeriu
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50 (04)
  • [9] Treatment of multidrug-resistant tuberculosis in Indonesia
    Hadiarto, M
    Tjandra, YA
    Hudoyo, A
    CHEMOTHERAPY, 1996, 42 : 24 - 29
  • [10] Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs
    Zuur, Marlanka A.
    Pasipanodya, Jotam G.
    van Soolingen, Dick
    van der Werf, Tjip S.
    Gumbo, Tawanda
    Alffenaar, Jan-Willem C.
    CLINICAL INFECTIOUS DISEASES, 2018, 67 (11) : 1743 - 1749